论文部分内容阅读
目的:建立一种可注射异体脂肪移植模型,观察兔异体脂肪干细胞(adipose-derived stem cells,ADSCs)复合自体脂肪颗粒(adipose granule,AG)和富血小板纤维蛋白(platelet-rich fibrin,PRF)移植后的形态学和免疫学的变化,为临床异体脂肪干细胞移植提供一种实验依据。方法:取30只健康新西兰家兔,随机分成5组:A组,(N=6),移植物为自体AG;B组,(N=6),自体AG+自体PRF;C组(N=6),自体AG+自体ADSCs:D组(N=6),自体AG+自体PRF+自体ADSCs,E组(N=6),实验组,自体AG+自体PRF+异体ADSCs。在术后1、3、6个月,大体外观、HE染色分析其形态学改变;免疫组化、外周血淋巴细胞亚群CD4/CD8比值、血浆IL2和IL4分析其免疫学改变。结果:术后1、3、6个月在大体外观、免疫组化等D、E两组与A、B、C三组比较均有显著性差异(P<0.05)。E组在淋巴亚群CD4/CD8、血浆IL-2、IL-4等与D组比较均无显著性差异(P>0.05)。结论:异体ADSCs复合自体PRF、AG能够显著提高移植脂肪组织的成活率,并且无明显免疫排斥反应,可为临床异体脂肪干细胞移植提供实验依据。
OBJECTIVE: To establish an injectable allogenic fat transplantation model and observe the effects of allogenic adipose-derived stem cells (ADSCs) combined with autologous adipose granule (AG) and platelet-rich fibrin (PRF) transplantation Morphological and immunological changes, providing an experimental basis for the clinical allogeneic ADSCs transplantation. Methods: Thirty healthy New Zealand rabbits were randomly divided into five groups: group A (n = 6) and autograft (group B) (n = 6) ), Autologous AG + autologous ADSCs: group D (N = 6), autologous AG + autologous PRF + autologous ADSCs, group E (N = 6), experimental group, autologous AG + autologous PRF + allogeneic ADSCs. At 1, 3 and 6 months postoperatively, gross appearance and HE staining were used to analyze the morphological changes. Immunohistochemistry, peripheral blood lymphocyte subsets CD4 / CD8 ratio, plasma IL2 and IL4 immunological changes were analyzed. Results: At 1, 3, and 6 months after operation, there were significant differences in appearance and immunohistochemistry between groups D and E and groups A, B and C (P <0.05). There was no significant difference between group E and group D in CD4 + CD8, IL-2 and IL-4 levels in lymphoid subgroups (P> 0.05). CONCLUSION: Allogeneic ADSCs combined with autologous PRF and AG can significantly improve the survival rate of adipose tissue transplanted, and no obvious immune rejection, which can provide experimental evidence for allogeneic adipose-derived stem cell transplantation.